Can a common diabetes drug protect the heart? new trial aims to find out

NCT ID NCT07288749

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial will test whether glimepiride, a standard diabetes pill, can reduce the risk of heart-related death, heart transplant, or worsening heart failure in people with type 2 diabetes and chronic heart failure. About 1,484 participants will receive either glimepiride or a placebo, alongside standard treatments for both conditions. The study aims to see if adding glimepiride improves outcomes over standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glimepiride (oral diabetes medication)
What this could lead to: If successful, this could show that glimepiride safely helps manage both diabetes and heart failure, reducing the risk of death or hospitalization.
What could go wrong: This is a large Phase 3 trial, but glimepiride is an older drug and may not outperform placebo in this specific heart failure population. Results may not apply outside China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE (CHF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure systolic heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE (CHF) TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Tongji Hostipal

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.